Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Yamagami W, Nagase S, Takahashi F, et al. Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol. 2017;28(2):e32.
   PubMed Web of Science ®Google Scholar
• Anglesio MS, Carey MS, Köbel M, et al. Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, june 24th, 2010. Gynecol Oncol. 2011;121(2):407–415.
   PubMed Web of Science ®Google Scholar
• Machida H, Matsuo K, Yamagami W, et al. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol. 2019;153(3):589–596.
   PubMed Web of Science ®Google Scholar
• Zhu C, Xu Z, Zhang T, et al. Updates of pathogenesis, diagnostic and therapeutic perspectives for ovarian clear cell carcinoma. J Cancer. 2021;12(8):2295–2316.
   PubMed Web of Science ®Google Scholar
• Tang H, Liu Y, Wang X, et al. Clear cell carcinoma of the ovary: clinicopathologic features and outcomes in a chinese cohort. Medicine (Baltimore). 2018;97(21):e10881.
   PubMed Web of Science ®Google Scholar
• Shu CA, Zhou Q, Jotwani AR, et al. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Gynecol Oncol. 2015;139(2):236–241.
   PubMed Web of Science ®Google Scholar
• D’Oria O, D’Augè TG, Baiocco E, et al. The role of preoperative frailty assessment in patients affected by gynecological cancer: a narrative review. Ital J Gynaecol Obstet. 2022;34(02):76–83.
   Google Scholar
• Metcalf RL, Fry DJ, Swindell R, et al. Thrombosis in ovarian cancer: a case control study. Br J Cancer. 2014;110(5):1118–1124.
   PubMed Web of Science ®Google Scholar
• Rubio-Salvador AR, Escudero-Vilaplana V, Marcos Rodríguez JA, et al. Cost of venous thromboembolic disease in patients with lung cancer: costecat study. Int J Environ Res Public Health. 2021;18(2):394.
   PubMed Web of Science ®Google Scholar
• Ratib S, Walker AJ, Card TR, et al. Risk of venous thromboembolism in hospitalised cancer patients in England-a cohort study. J Hematol Oncol. 2016;9(1):60.
   PubMed Web of Science ®Google Scholar
• Duska LR, Garrett L, Henretta M, et al. When 'never-events’ occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010;116(3):374–377.
   PubMed Web of Science ®Google Scholar
• Lee HY, Hong JH, Byun JH, et al. Clinical characteristics of clear cell ovarian cancer: a retrospective multicenter experience of 308 patients in South Korea. Cancer Res Treat. 2020;52(1):277–283.
   PubMed Web of Science ®Google Scholar
• Tamura R, Yoshihara K, Matsuo K, et al. Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma. Gynecol Oncol. 2021;163(2):327–333.
   PubMed Web of Science ®Google Scholar
• Cocco E, Varughese J, Buza N, et al. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor. Clin Exp Metastasis. 2011;28(7):689–700.
   PubMed Web of Science ®Google Scholar
• Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2011;39(2):91–92.
   PubMed Web of Science ®Google Scholar
• Shimizu A, Sawada K, Shiomi M, et al. Direct oral anticoagulants are effective and safe for the treatment of venous thromboembolism associated with gynecological cancers. Int J Gynaecol Obstet. 2019;147(2):252–257.
   PubMed Web of Science ®Google Scholar
• Shigemi D, Matsuhashi T, Yamada T, et al. Preoperative screening of thromboembolism using plasma D-dimer test and proximal vein compression ultrasonography in japanese gynecologic patients. Ann Med Surg (Lond). 2017;15:52–55.
   PubMedGoogle Scholar
• Komatsu H, Shimada M, Osaku D, et al. Deep vein thrombosis and serum D-dimer after pelvic lymphadenectomy in gynecological cancer. Int J Gynecol Cancer. 2020;30(6):860–864.
   PubMed Web of Science ®Google Scholar
• Takano H, Nakajima K, Nagayoshi Y, et al. Clinical associations of trousseau’s syndrome associated with cerebral infarction and ovarian cancer. J Gynecol Oncol. 2018;29(5):e67.
   PubMed Web of Science ®Google Scholar
• Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007;96(2):290–295.
   PubMed Web of Science ®Google Scholar
• Takasaki K, Miyamoto M, Takano M, et al. Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma. Int J Clin Oncol. 2019;24(10):1273–1283.
   PubMed Web of Science ®Google Scholar
• Yamanoi K, Mandai M, Suzuki A, et al. Synchronous primary corpus and ovarian cancer: high incidence of endometriosis and thrombosis. Oncol Lett. 2012;4(3):375–380.
   PubMed Web of Science ®Google Scholar
• Sakurai M, Matsumoto K, Gosho M, et al. Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism. Int J Gynecol Cancer. 2017;27(1):37–43.
   PubMed Web of Science ®Google Scholar
• Tasaka N, Minaguchi T, Hosokawa Y, et al. Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer. J Obstet Gynaecol Res. 2020;46(5):765–773.
   PubMed Web of Science ®Google Scholar
• Kawaguchi R, Furukawa N, Kobayashi H. Cut-off value of D-dimer for prediction of deep venous thrombosis before treatment in ovarian cancer. J Gynecol Oncol. 2012;23(2):98–102.
   PubMed Web of Science ®Google Scholar
• Satoh T, Oki A, Uno K, et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer. 2007;97(8):1053–1057.
   PubMed Web of Science ®Google Scholar
• Ebina Y, Uchiyama M, Imafuku H, et al. Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine. 2018;97(23):e11009.
   PubMed Web of Science ®Google Scholar
• Bakhru A. Effect of ovarian tumor characteristics on venous thromboembolic risk. J Gynecol Oncol. 2013;24(1):52–58.
   PubMed Web of Science ®Google Scholar
• Kumar A, Hurtt CC, Cliby WA, et al. Concomitant venous thromboembolism at the time of primary EOC diagnosis: perioperative outcomes and survival analyses. Gynecol Oncol. 2017;147(3):514–520.
   PubMed Web of Science ®Google Scholar
• Wield AM, Walsh CS, Rimel B, et al. Aspirin use correlates with survival in women with clear cell ovarian cancer. Gynecol Oncol Rep. 2018;25:78–81.
   PubMed Web of Science ®Google Scholar
• Goff BA, de la Cuesta RS, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60(3):412–417.
   PubMed Web of Science ®Google Scholar
• Diaz ES, Walts AE, Karlan BY, et al. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. 2013;131(3):541–545.
   PubMed Web of Science ®Google Scholar
• Recio FO, Piver MS, Hempling RE, et al. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum‐based chemotherapy. Cancer Interdisc Inter J Am Cancer Soc. 1996;78(10):2157–2163.
   Google Scholar
• Eltabbakh GH, Mount SL, Beatty B, et al. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol. 2006;93(5):379–386.
   PubMed Web of Science ®Google Scholar
• Cohen JG, Prendergast E, Geddings JE, et al. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecol Oncol. 2017;146(1):146–152.
   PubMed Web of Science ®Google Scholar
• Greco PS, Bazzi AA, McLean K, et al. Incidence and timing of thromboembolic events in patients with ovarian cancer undergoing neoadjuvant chemotherapy. Obstet Gynecol. 2017;129(6):979–985.
   PubMed Web of Science ®Google Scholar
• Zhu C, Zhu J, Qian L, et al. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer. 2021;21(1):1–15.
   PubMed Web of Science ®Google Scholar
• Liang S, Tang W, Ye S, et al. Incidence and risk factors of preoperative venous thromboembolism and pulmonary embolism in patients with ovarian cancer. Thromb Res. 2020;190:129–134.
   PubMed Web of Science ®Google Scholar
• Ye S, Zhang W, Yang J, et al. Pattern of venous thromboembolism occurrence in gynecologic malignancy: incidence, timing, and distribution a 10-year retrospective single-institutional study. Medicine. 2015;94(50):e2316.
   PubMed Web of Science ®Google Scholar
• Ye S, Yang J, Cao D, et al. Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study. PLoS One. 2015;10(3):e0121818.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou H, Zhong G, et al. Development and validation of a nomogram to predict the probability of venous thromboembolism in patients with epithelial ovarian cancer. Clin Appl Thromb Hemost. 2022;28:10760296221095558.
   Web of Science ®Google Scholar
• Li J, Cao D. Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma. Front Oncol. 2022;12:956380–956380.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhu C, Shen Z, et al. Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period. Eur J Surg Oncol. 2020;46(5):855–861.
   PubMed Web of Science ®Google Scholar
• Saadeh FA, Langhe R, Galvin D, et al. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. Thromb Res. 2016;139:135–141.
   PubMed Web of Science ®Google Scholar
• Abu Saadeh F, Norris L, O'Toole S, et al. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):214–218.
   PubMed Web of Science ®Google Scholar
• Abu Saadeh F, Norris L, O'Toole S, et al. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer-relationship with venous thrombosis risk. Thromb Res. 2013;132(5):627–634.
   PubMed Web of Science ®Google Scholar
• Oxley SG, Achampong YA, Sambandan N, et al. Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: a retrospective study. Acta Obstet Gynecol Scand. 2021;100(11):2091–2096.
   PubMed Web of Science ®Google Scholar
• Pather S, Quinn M. Clear-cell cancer of the ovary—is it chemosensitive? Int J Gynecol Cancer. 2005;15(3):432–437.
   PubMed Web of Science ®Google Scholar
• Matsuura Y, Robertson G, Marsden DE, et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol. 2007;104(2):406–410.
   PubMed Web of Science ®Google Scholar
• Lim MC, Lee HS, Kang S, et al. Minimizing tumor burden by extensive cytoreductive surgery decreases postoperative venous thromboembolism in ovarian clear cell carcinoma. Arch Gynecol Obstet. 2010;281(2):329–334.
   PubMed Web of Science ®Google Scholar
• Kahr HS, Christiansen OB, Grove A, et al. Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study. Thromb Res. 2019;181:112–119.
   PubMed Web of Science ®Google Scholar
• Fotopoulou C, Karavas A, Trappe R, et al. Venous thromboembolism in recurrent ovarian cancer-patients: a systematic evaluation of the North-Eastern german society of gynaecologic oncology ovarian cancer study group (NOGGO). Thromb Res. 2009;124(5):531–535.
   PubMed Web of Science ®Google Scholar
• Black KA, Ghosh S, Singh N, et al. Venous thromboembolism in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer and impact on survival. J Obstet Gynaecol Can. 2021;43(12):1380–1387.
   PubMed Web of Science ®Google Scholar
• Supoken A, Kleebkaow P, Chumworathayi B, et al. Elevated preoperative platelet to lymphocyte ratio associated with decreased survival of women with ovarian clear cell carcinoma. Asian Pac J Cancer Prev. 2014;15(24):10831–10836.
   PubMedGoogle Scholar
• Matsuo K, Hasegawa K, Yoshino K, et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer. 2015;51(14):1978–1988.
   PubMed Web of Science ®Google Scholar
• Miyake R, Yamada Y, Yamanaka S, et al. Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results. Mol Clin Oncol. 2022;16(2):46.
   PubMed Web of Science ®Google Scholar
• Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers. 2018;10(10):380.
   PubMed Web of Science ®Google Scholar
• Weeks KS, Herbach E, McDonald M, et al. Meta-Analysis of VTE risk: ovarian cancer patients by stage, histology, cytoreduction, and ascites at diagnosis. Obstet Gynecol Int. 2020;2020:2374716.
   PubMed Web of Science ®Google Scholar
• Okamoto A, Sehouli J, Yanaihara N, et al. Somatic copy number alterations associated with japanese or endometriosis in ovarian clear cell adenocarcinoma. PLoS One. 2015;10(2):e0116977.
   PubMed Web of Science ®Google Scholar
• Saerens M, De Jaeghere EA, Kanervo H, et al. Risk of Thrombo-Embolic events in ovarian cancer: does bevacizumab tilt the scale? A systematic review and Meta-Analysis. Cancers. 2021;13(18):4603.
   PubMed Web of Science ®Google Scholar
• Strøm Kahr H, Christiansen OB, Juul Riddersholm S, et al. The timing of venous thromboembolism in ovarian cancer patients: a nationwide danish cohort study. J Thromb Haemost. 2021;19(4):992–1000.
   PubMed Web of Science ®Google Scholar
• Di Donato V, D'Oria O, Giannini A, et al. Age-Adjusted charlson comorbidity index predicts survival in endometrial cancer patients. Gynecol Obstet Invest. 2022;87(3-4):191–199.
   PubMed Web of Science ®Google Scholar
• Giannakeas V, Kotsopoulos J, Brooks JD, et al. Platelet count and survival after cancer. Cancers (Basel). 2022;14(3):549.
   PubMed Web of Science ®Google Scholar
• Hufnagel DH, Cozzi GD, Crispens MA, et al. Platelets, thrombocytosis, and ovarian cancer prognosis: surveying the landscape of the literature. Int J Mol Sci. 2020;21(21):8169.
   PubMed Web of Science ®Google Scholar